November 18, 2015
The full Federal Circuit has a chance to narrow the reach of the on-sale bar after agreeing to review a decision that invalidated patents for the blood-thinning drug Angiomax under a theory that attorneys say could put small drugmakers at a disadvantage.
November 13, 2015
The full Federal Circuit on Friday agreed to review a panel decision overruling a trial judge and invalidating two of The Medicines Co.'s patents for the blood-thinning drug Angiomax, positioning the court to consider questions about what constitutes an on-sale bar.
July 02, 2015
The Federal Circuit on Thursday invalidated two of The Medicines Co.'s patents for the blood thinning drug Angiomax, finding that the claimed process was offered for sale before the patent applications were filed, in a victory for Hospira Inc., which is planning a generic version of the drug.